Showing results (951-960 of 4,380) with videos related to
Sort By:
Pageof 438
ACS Medicinal Chemistry Letters|June 19, 2024
SARS-CoV-2 Main Protease Inhibitors That Leverage Unique Interactions with the Solvent Exposed S3 Site of the EnzymeLauren R Blankenship, Kai S Yang, Veerabhadra R Vulupala, et al.ACS Medicinal Chemistry Letters|June 19, 2024
The Inhibitors of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT-1) Protease as Potential Treatment of ABC-DLBCL and Similar DiseasesAhmed F Abdel-MagidACS Medicinal Chemistry Letters|June 19, 2024
Potent, Selective, and Orally Bioavailable Quinazoline-Based STK17A/B Dual InhibitorsSana Chaudhry, Jesus R Castro, Tulasigeri M Totiger, et al.ACS Medicinal Chemistry Letters|June 19, 2024
Novel HSD17B13 Inhibitors for Treating Liver DiseasesRam W SabnisACS Medicinal Chemistry Letters|June 19, 2024
Novel 2,7-Naphthyridine Compounds as MASTL Inhibitors for Treating CancerRam W SabnisACS Medicinal Chemistry Letters|June 19, 2024
Development of Biochemical and Cellular Probes to Study RIPK1 Target EngagementXin Yu, Hanfeng Lin, Feng Li, et al.ACS Medicinal Chemistry Letters|June 19, 2024
2-Aminopyridines as Potent and Selective Nav1.8 Inhibitors Exhibiting Efficacy in a Nonhuman Primate Pain ModelMichael J Breslin, Jeffrey W Schubert, Deping Wang, et al.ACS Medicinal Chemistry Letters|June 19, 2024
Novel Tyrosine Kinase 2 Inhibitors for Treating Autoimmune and Inflammatory DiseasesRam W SabnisACS Medicinal Chemistry Letters|May 15, 2024
Analysis of the Physicochemical Properties of Anti-Schistosomal Compounds to Identify Next-Generation LeadsDiego González Cabrera, Jennifer Keiser, Thomas SpangenbergACS Medicinal Chemistry Letters|May 15, 2024
Design, Synthesis, and Bioevaluation of Transcriptional Enhanced Assocciated Domain (TEAD) PROTAC DegradersHuajie Li, Zhiming Ge, Kexin Lin, et al.Pageof 438